ArticleThe Journal of infectious diseases2022

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model.

Alexia Kieffer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.